Alkeus raises funds to launch Stargardt disease therapy gildeuretinol

Alkeus Pharmaceuticals has raised $150m in Series B financing to support the registration and launch of gildeuretinol (ALK-001) to treat …

Magazine: The journey of first generics

In a 2022 annual report, the US Food and Drug Administration’s (FDA) Office of Generic Drugs stated it had approved …

Avadel Pharmaceuticals launches excessive daytime sleepiness therapy in US

Avadel Pharmaceuticals has introduced LUMRYZ (sodium oxybate) for commercial use in the US to treat cataplexy (excessive daytime sleepiness, or …

Selvita and the University of Oxford join forces to tackle Parkinson’s disease

The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance …

ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data

Summit Therapeutics has announced data for its novel investigational bispecific antibody, ivonescimab, known as SMT112 or AK112 in a non-small …